Orchid s Revenues Gain 5.3 Percent in Q2 as Loss Narrows

Jul 28, 2005

NEW YORK, July 28 (GenomeWeb News) - Orchid Cellmark today reported increased revenues and narrowed losses for the second quarter of 2005.

The company had $15.8 million in revenues, up 5.3 percent from $15 million for the second quarter of 2004.

Research and development costs stayed flat, at $417,000, compared to $454,000 during last year's second quarter.

Orchid's net loss totaled $1.8 million, or $.07 per share, down from $2.1 million, or $.10 per share, for the year-ago period.

As of June 30, Orchid had $12.7 million in cash and cash equivalents, and $14.7 million in short-term investments.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.